Daratumumab hyaluronidase is a combination therapy used for certain blood cancers, specifically multiple myeloma [1]. The hyaluronidase component is an enzyme that helps the body absorb the daratumumab, allowing it to be administered subcutaneously (under the skin) rather than intravenously (into a vein) [1]. This formulation can lead to shorter administration times [1].
How is Daratumumab Hyaluronidase Administered?
Daratumumab hyaluronidase is given as an injection under the skin [1]. This subcutaneous administration is a key feature that differentiates it from earlier intravenous formulations of daratumumab [1]. The injection is typically given by a healthcare professional [1].
What Cancers Does Daratumumab Hyaluronidase Treat?
This combination therapy is indicated for adult patients with multiple myeloma, a type of cancer that affects plasma cells in the bone marrow [1]. It is used in various settings, including newly diagnosed patients who are eligible for autologous stem cell transplant, those who have received at least one prior therapy, and patients with relapsed or refractory multiple myeloma [1].
What is the Difference Between Daratumumab and Daratumumab Hyaluronidase?
The primary difference lies in the formulation and route of administration [1]. Daratumumab alone is an antibody that can be given intravenously. Daratumumab hyaluronidase is a fixed-dose combination that includes the daratumumab antibody and the enzyme hyaluronidase, enabling subcutaneous injection [1]. The addition of hyaluronidase allows for faster drug absorption under the skin, reducing infusion times compared to the intravenous method [1].
How Long Does Treatment with Daratumumab Hyaluronidase Last?
The duration of treatment with daratumumab hyaluronidase depends on the specific treatment regimen, the patient's response to the medication, and the treating physician's recommendation [1]. It is typically administered on a cyclical basis as part of a multi-drug regimen [1].
What are the Potential Side Effects of Daratumumab Hyaluronidase?
Common side effects can include upper respiratory tract infections, nausea, diarrhea, fever, fatigue, back pain, and peripheral neuropathy [1]. More serious side effects, though less common, can occur and include infusion-related reactions, especially during the first dose, and reactivation of herpes zoster virus [1].
When Does the Patent for Daratumumab Hyaluronidase Expire?
Patent expiry dates for pharmaceutical drugs can be complex and subject to various legal challenges and extensions. DrugPatentWatch.com tracks patent information for medications. Specific patent expiry timelines for daratumumab hyaluronidase can be found by consulting detailed patent databases and resources like DrugPatentWatch.com [2].
What Other Treatments are Available for Multiple Myeloma?
Multiple myeloma is treated with a variety of agents, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies (such as daratumumab), and chemotherapy [1]. Treatment strategies are often individualized based on patient factors, disease stage, and prior therapies [1].
Who Makes Daratumumab Hyaluronidase?
Daratumumab hyaluronidase is developed and marketed by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson [3].
Can Biosimilars of Daratumumab Hyaluronidase Be Developed?
The development and approval of biosimilars for complex biologic drugs like daratumumab hyaluronidase are possible, but they undergo rigorous regulatory review to demonstrate similarity to the reference product in terms of safety, efficacy, and quality [4]. The timeline for biosimilar market entry is often influenced by patent protection and exclusivity periods [4].
---
Sources:
[1] https://www.cancernetwork.com/view/daratumumab-hyaluronidase-subcutaneous-injection-combination-for-multiple-myeloma
[2] https://drugpatentwatch.com/
[3] https://www.janssen.com/
[4] https://www.fda.gov/drugs/biosimilars/what-biosimilar